ES2012803B3 - Sales de amlodipina. - Google Patents

Sales de amlodipina.

Info

Publication number
ES2012803B3
ES2012803B3 ES87302767T ES87302767T ES2012803B3 ES 2012803 B3 ES2012803 B3 ES 2012803B3 ES 87302767 T ES87302767 T ES 87302767T ES 87302767 T ES87302767 T ES 87302767T ES 2012803 B3 ES2012803 B3 ES 2012803B3
Authority
ES
Spain
Prior art keywords
amlodipine salts
amlodipine
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87302767T
Other languages
English (en)
Spanish (es)
Inventor
Edward Davison
James Ingram Wells
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER Ltd
Pfizer Ltd Great Britain
Original Assignee
PFIZER Ltd
Pfizer Ltd Great Britain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10595731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2012803(B3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by PFIZER Ltd, Pfizer Ltd Great Britain filed Critical PFIZER Ltd
Application granted granted Critical
Publication of ES2012803B3 publication Critical patent/ES2012803B3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
ES87302767T 1986-04-04 1987-03-31 Sales de amlodipina. Expired - Lifetime ES2012803B3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868608335A GB8608335D0 (en) 1986-04-04 1986-04-04 Pharmaceutically acceptable salts

Publications (1)

Publication Number Publication Date
ES2012803B3 true ES2012803B3 (es) 1990-04-16

Family

ID=10595731

Family Applications (2)

Application Number Title Priority Date Filing Date
ES87302767T Expired - Lifetime ES2012803B3 (es) 1986-04-04 1987-03-31 Sales de amlodipina.
ES8700965A Expired ES2002599A6 (es) 1986-04-04 1987-04-03 Un procedimiento para la preparacion de la sal de besilato de amlodipina

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES8700965A Expired ES2002599A6 (es) 1986-04-04 1987-04-03 Un procedimiento para la preparacion de la sal de besilato de amlodipina

Country Status (47)

Country Link
US (1) US4879303A (en:Method)
EP (1) EP0244944B1 (en:Method)
JP (1) JPS62240660A (en:Method)
KR (1) KR950006710B1 (en:Method)
CN (1) CN1023800C (en:Method)
AP (1) AP50A (en:Method)
AR (1) AR242562A1 (en:Method)
AT (1) ATE49752T1 (en:Method)
BE (1) BE1000130A4 (en:Method)
BG (1) BG60698B2 (en:Method)
CA (1) CA1321393C (en:Method)
CS (1) CS265237B2 (en:Method)
CY (1) CY1669A (en:Method)
CZ (1) CZ289095B6 (en:Method)
DD (1) DD265142A5 (en:Method)
DE (2) DE3710457A1 (en:Method)
DK (1) DK171708B1 (en:Method)
EC (1) ECSP941129A (en:Method)
EG (1) EG18266A (en:Method)
ES (2) ES2012803B3 (en:Method)
FI (1) FI85017C (en:Method)
FR (1) FR2596758B1 (en:Method)
GB (2) GB8608335D0 (en:Method)
GR (2) GR870525B (en:Method)
HK (1) HK76092A (en:Method)
HU (1) HU196962B (en:Method)
IE (1) IE59457B1 (en:Method)
IL (1) IL82101A (en:Method)
IN (1) IN168414B (en:Method)
IT (1) IT1203853B (en:Method)
LU (1) LU86812A1 (en:Method)
MA (1) MA20938A1 (en:Method)
MX (1) MX5847A (en:Method)
MY (1) MY101177A (en:Method)
NL (1) NL8700791A (en:Method)
NO (1) NO172181C (en:Method)
NZ (1) NZ219868A (en:Method)
PH (1) PH24348A (en:Method)
PL (1) PL149532B1 (en:Method)
PT (1) PT84611B (en:Method)
SE (1) SE463457B (en:Method)
SG (1) SG59692G (en:Method)
SK (1) SK278435B6 (en:Method)
SU (1) SU1498388A3 (en:Method)
UA (1) UA6344A1 (en:Method)
YU (1) YU44801B (en:Method)
ZA (1) ZA872439B (en:Method)

Families Citing this family (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
US6057344A (en) 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
EP0661970A1 (en) * 1991-11-26 1995-07-12 Sepracor, Inc. Methods and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine
US6162802A (en) * 1992-03-10 2000-12-19 Papa; Joseph Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor
AT399718B (de) * 1992-04-16 1995-07-25 Lek Tovarna Farmacevtskih Inklusionskomplexe von optisch aktiven und racemischen 1,4-dihydropyridinen mit methyl-beta- cyclodextrin oder anderen cyclodextrinderivaten, ein verfahren zur herstellung von optisch aktiven dihydropyridinen und deren inklusionskomplexen und diese komplexe enthaltende pharmazeutische formulierungen
US5389654A (en) * 1992-11-26 1995-02-14 Lek, Tovarna, Farmacevtskih In Kemicnih . . . 3-ethyl 5-methyl(±)2-[2-(N-tritylamino)ethoxymethyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-6-methyl-3,5-pyridinedicarboxylate
SI9200344B (sl) * 1992-11-26 1998-06-30 Lek, Postopek za pripravo amlodipin benzensulfonata
USRE39384E1 (en) 1993-09-01 2006-11-07 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivatives
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
MX9706957A (es) 1995-03-16 1997-11-29 Pfizer Composicion que contiene amlodipina, o una sal, o felodipina y un inhibidor de enzima convertidora de angiotensina.
HU221810B1 (hu) * 1997-08-12 2003-01-28 EGIS Gyógyszergyár Rt. Eljárás amlodipin-bezilát előállítására és az eljárás intermedierjei
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
AU6767198A (en) * 1998-03-26 1999-05-03 Dr. Reddy's Laboratories Limited Stable pharmaceutical composition containing amlodipine besylate and atenol ol
RU2188636C2 (ru) * 1998-03-26 2002-09-10 Др. Редди'С Лабораторис Лтд. Стабильный фармацевтический препарат, содержащий амлодипина безилат и атенолол
PL189666B1 (pl) * 1998-04-09 2005-09-30 Adamed Sp Z Oo Sposób otrzymywania benzenosulfonianu amlodypiny
AU753486B2 (en) 1998-07-10 2002-10-17 Novartis Ag Method of treatment and pharmaceutical composition
US20070072828A1 (en) * 1998-07-24 2007-03-29 Yoo Seo H Bile preparations for colorectal disorders
US7303768B2 (en) * 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US20050158408A1 (en) * 1998-07-24 2005-07-21 Yoo Seo H. Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
US7772220B2 (en) * 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
UA33033A (uk) * 1998-10-16 2001-02-15 Др.Редіс Леборетрис Лтд Спосіб одержання безилату амлодипіну
US7129265B2 (en) * 1999-04-23 2006-10-31 Mason R Preston Synergistic effects of amlodipine and atorvastatin metabolite as a basis for combination therapy
RU2142942C1 (ru) * 1999-04-28 1999-12-20 Дж. Б.Кемикалс энд Фармасьютикалс Лтд. Способ получения монобензолсульфоната 3-этил-5-метилового эфира 2-[(2-аминоэтокси)метил]-4-(2-хлорфенил)-1,4-дигидро-6-метил-3,5-пиридинди карбоновой кислоты
WO2000073298A1 (en) 1999-05-27 2000-12-07 Pfizer Products Inc. Mutual prodrugs of amlodipine and atorvastatin
HN2000000050A (es) 1999-05-27 2001-02-02 Pfizer Prod Inc Sal mutua de amlodipino y atorvastatina
RU2161156C1 (ru) * 1999-06-01 2000-12-27 Джи.Б.Кемикалс Энд Фармасьютикалс Лтд Способ получения 3-этил-5-метиловый эфир 2-[2-(n-фталимидо)-этоксиметил]-4-(2-хлорфенил)-1,4-дигидро-6-метил-3,5- пиридиндикарбоновой кислоты
UA72768C2 (en) 1999-07-05 2005-04-15 Richter Gedeon Vegyeszet A method for obtaining amilodipine benzenesulphonate
RU2146672C1 (ru) * 1999-10-13 2000-03-20 Др.Редди'С Лабораторис Лтд. Способ получения 3-этил-5-метил(±)2[2-аминоэтокси)-метил]-4-(2-хлорфенил)-1,4-дигидро- 6-метил-3,5-пиридиндикарбоксилат монобензолсульфоната
US6521647B2 (en) 2000-04-04 2003-02-18 Pfizer Inc. Treatment of renal disorders
WO2002011723A1 (en) 2000-08-04 2002-02-14 Mason R Preston Synergistic effect of amlodipine and atorvastatin
US6737430B2 (en) 2000-11-09 2004-05-18 Pfizer, Inc. Mutual prodrug of amlodipine and atorvastatin
GB0027410D0 (en) * 2000-11-09 2000-12-27 Pfizer Ltd Mutual prodrug of amlodipine and atorvastatin
US6653481B2 (en) 2000-12-29 2003-11-25 Synthon Bv Process for making amlodipine
BR0116554A (pt) 2000-12-29 2004-02-03 Pfizer Ltd Composto, composição farmacêutica para o tratamento da angina ou hipertensão, processo, processo para o tratamento ou prevenção da angina ou hipertensão, composição do ingrediente farmaceuticamente ativo e composição farmacêutica para o tratamento ou prevenção da angina ou hipertensão
AT5874U1 (de) 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
WO2002053539A1 (en) 2000-12-29 2002-07-11 Pfizer Limited Amlodipine hemimaleate
BR0116553A (pt) 2000-12-29 2004-02-03 Pfizer Ltd Composto, composição farmacêutica para tratamento de angina ou hipertensão, processo, processo para tratamento ou prevenção de angina ou hipertensão, composição de ingredientes farmaceuticamente ativos, composição farmacêutica para tratamento ou prevenção de angina ou hipertensão e processo para tratar ou prevenir angina ou hipertensão
US7335380B2 (en) 2000-12-29 2008-02-26 Synthon Ip Inc. Amlodipine free base
CA2433181C (en) 2000-12-29 2005-11-22 Pfizer Limited Amlodipine hemifumarate
MXPA03005882A (es) 2000-12-29 2005-04-19 Pfizer Ltd Derivado amida de amlodipina.
EP1309555B1 (en) * 2000-12-29 2005-07-27 Pfizer Limited Process for making amlodipine maleate
CA2433284A1 (en) 2000-12-29 2002-07-11 Pfizer Limited Reference standards and processes for determining the purity or stability of amlodipine maleate
DK1221438T3 (da) * 2001-01-09 2007-06-18 Siegfried Generics Int Ag Salte af Amlodipinmesylat
GB0103046D0 (en) 2001-02-07 2001-03-21 Novartis Ag Organic Compounds
KR100452491B1 (ko) * 2001-03-29 2004-10-12 한미약품 주식회사 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
US20030027848A1 (en) * 2001-06-15 2003-02-06 Anne Billotte Stabilized formulations
EP1435954B1 (en) 2001-07-06 2010-01-13 LEK Pharmaceuticals D.D. A PROCESS FOR THE PREPARATION OF HIGHlLY PUREAMLODIPINE BENZENESULFONATE
US20030220310A1 (en) * 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US6680334B2 (en) 2001-08-28 2004-01-20 Pfizer Inc Crystalline material
US7544681B2 (en) 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
US20040001886A1 (en) * 2001-10-17 2004-01-01 Dr. Reddy's Laboratories Limited Stabilized pharmaceutical formulations containing amlodipine maleate
US6828339B2 (en) * 2001-11-21 2004-12-07 Synthon Bv Amlodipine salt forms and processes for preparing them
HU226642B1 (en) * 2001-12-17 2009-05-28 Egis Gyogyszergyar Nyilvanosan Amlodipine bezylate tablets having extended stability and process for producing the same
NL1019882C2 (nl) * 2002-02-01 2003-08-04 Synthon Licensing Amlodipine vrije base.
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
JP4287752B2 (ja) * 2002-04-13 2009-07-01 ハンリム ファーマシューティカル カンパニー リミテッド アムロジピンニコチネート及びその製造方法
CN101648028B (zh) 2002-05-06 2012-11-21 恩多塞特公司 维生素-定向的显象剂
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
SI21233A (sl) * 2002-05-31 2003-12-31 LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d. Kristalni hidratni obliki amlodipin benzensulfonata visoke čistote, postopki za njuno pripravo in uporaba
US6699892B2 (en) 2002-06-04 2004-03-02 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salt of amlodipine and method of preparing the same
RU2221784C1 (ru) * 2002-07-05 2004-01-20 Марвел Лайфсайнсез Прайвит Лимитед Способ получения бензолсульфоната амлодипина
KR100496436B1 (ko) 2002-07-30 2005-06-20 씨제이 주식회사 암로디핀의 유기산염
KR100462304B1 (ko) * 2002-07-30 2004-12-17 씨제이 주식회사 암로디핀의 유기산염
KR20040011751A (ko) * 2002-07-30 2004-02-11 씨제이 주식회사 암로디핀의 유기산염
KR100538641B1 (ko) 2002-07-30 2005-12-22 씨제이 주식회사 암로디핀의 유기산염
KR100467669B1 (ko) * 2002-08-21 2005-01-24 씨제이 주식회사 암로디핀의 유기산염
HRP20050205A2 (en) 2002-08-29 2005-10-31 Taisho Pharmaceutical Co. Benzensulfonate of 4-fluoro-2-cyanopyrrolidine derivative
US6784297B2 (en) * 2002-09-04 2004-08-31 Kopran Limited Process for the preparation of anti-ischemic and anti-hypertensive drug amlodipine besylate
CA2525700C (en) 2002-09-11 2009-11-24 Hanlim Pharmaceutical Co., Ltd. S-(-)-amlodipine nicotinate and process for the preparation thereof
WO2004026834A1 (en) * 2002-09-19 2004-04-01 Cj Corporation Crystalline organic acid salt of amlodipine
US7166641B2 (en) * 2002-10-02 2007-01-23 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same
EP1407773A1 (en) * 2002-10-08 2004-04-14 Council of Scientific and Industrial Research A process for the preparation of s (-) amlodipine salts
US20040072879A1 (en) * 2002-10-10 2004-04-15 Dr. Reddy's Laboratories Limited Crystalline 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine maleate salt (Amlodipine)
AU2002368531A1 (en) * 2002-12-30 2004-07-22 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Isolation of dihydropyridine derivative and preparation salts thereof
JP2007528349A (ja) 2003-01-27 2007-10-11 ハンミ ファーム． シーオー．， エルティーディー． 高い安定性を有する無定形アムロジピンカムシレート、その製造方法及びこれを含む経口投与用組成物
CA2514921C (en) * 2003-01-31 2013-04-30 Sankyo Company, Limited Combined use of olmesartan medoxomil and azelnidipine or amlodipine for the treatment of arteriosclerosis and hypertension
KR20040072363A (ko) * 2003-02-12 2004-08-18 주식회사 대웅 신규한 암로디핀 사이클라메이트 염 및 그의 제조방법
US20060270715A1 (en) * 2003-02-28 2006-11-30 Singh Romi B Dosage forms of amlodipine and processes for their preparation
EP2865681A3 (en) 2003-04-25 2015-08-19 Cadila Healthcare Limited Salts of Clopidogrel besylate and process for preparation
GB2415696B (en) * 2003-04-25 2007-06-20 Cipla Ltd Process for preparing amlodipine mesylate monohydrate
JP2007516227A (ja) * 2003-05-16 2007-06-21 アンビット バイオサイエンシス コーポレーション ピロール化合物およびその使用
US20050182125A1 (en) * 2003-05-16 2005-08-18 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
AP1963A (en) 2003-05-30 2009-03-03 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as HMG-co inhibitors
RU2239433C1 (ru) * 2003-06-09 2004-11-10 Закрытое акционерное общество "Фармацевтическое предприятие "Оболенское" Лекарственная форма, обладающая вазодилатирующим, антиангинальным, гипотензивным и спазмолитическим действием, и способ ее изготовления
US7145125B2 (en) 2003-06-23 2006-12-05 Advanced Optical Technologies, Llc Integrating chamber cone light using LED sources
US20050048118A1 (en) * 2003-07-25 2005-03-03 Joan Cucala Escoi Modified release venlafaxine hydrochloride tablets
WO2005042485A1 (en) * 2003-10-30 2005-05-12 Sk Chemicals, Co., Ltd. Acid added salts of amlodipine
KR100841409B1 (ko) * 2003-12-16 2008-06-25 에스케이케미칼주식회사 암로디핀 겐티세이트 염과 이의 제조방법
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20060035940A1 (en) * 2004-03-16 2006-02-16 Sepracor Inc. (S)-Amlodipine malate
JP4880591B2 (ja) 2004-06-04 2012-02-22 テバ ファーマシューティカル インダストリーズ リミティド イルベサルタンを含む医薬組成物
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
CA2577268A1 (en) * 2004-08-30 2006-03-09 Seo Hong Yoo Neuroprotective effect of solubilized udca in focal ischemic model
BRPI0518191A (pt) * 2004-10-15 2008-11-04 Seo Hong Yoo métodos e composições para reduzir a toxicidade de um composto farmacêutico
EP2255812A1 (en) * 2004-11-01 2010-12-01 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
BRPI0518300A2 (pt) * 2004-11-23 2008-11-11 Warner Lambert Co derivados de Ácido 7-(2h-pirazol-3-il)-3,5-diidràxi-heptanàico como inibidores da hmg co-a reductase para o tratamento de lipidemia
WO2006059217A1 (en) * 2004-12-01 2006-06-08 Ranbaxy Laboratories Limited Stable solid dosage forms of amlodipine besylate and processes for their preparation
WO2006070248A1 (en) * 2004-12-28 2006-07-06 Ranbaxy Laboratories Limited Methods for the preparation of stable pharmaceutical solid dosage forms of atorvastatin and amlodipine
WO2006085208A2 (en) * 2005-02-11 2006-08-17 Ranbaxy Laboratories Limited Stable solid dosage forms of amlodipine and benazepril
AU2006256369B2 (en) * 2005-06-07 2012-08-02 Bar-Ilan University Novel salts of conjugated psychotropic drugs and processes of preparing same
CA2613417C (en) * 2005-06-27 2011-11-29 Daiichi Sankyo Company, Limited Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker
ES2303198T3 (es) * 2005-09-28 2008-08-01 Teva Pharmaceutical Industries Ltd. Combinaciones estables de besilato de amlodipina e hidrocloruro de benazeprilo.
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
AU2006313430B2 (en) 2005-11-08 2012-09-06 Ranbaxy Laboratories Limited Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
FR2894826B1 (fr) * 2005-12-21 2010-10-22 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur calcique et les compositions pharmaceutiques qui la contiennent
US8377990B2 (en) 2006-07-17 2013-02-19 Ramot At Tel-Aviv University Ltd. Conjugates comprising a psychotropic drug or a GABA agonist and an organic acid and their use in treating pain and other CNS disorders
KR100795313B1 (ko) 2006-09-05 2008-01-21 현대약품 주식회사 암로디핀 베실레이트를 포함하는 약학 조성물
TWI399223B (zh) 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
US20080096863A1 (en) * 2006-10-19 2008-04-24 Torrent Pharmaceuticals Limited Stable pharmaceutical compositions of calcium channel blocker and an ACE inhibitor
CN101167724B (zh) * 2006-10-25 2012-08-22 北京华安佛医药研究中心有限公司 含有氨氯地平的药物组合物在制备治疗下尿路疾病药物中的用途
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
CA2673336A1 (en) * 2006-12-21 2008-06-26 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
WO2008093984A1 (en) 2007-01-29 2008-08-07 Hanall Pharmaceutical Company. Ltd N, n- dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same
US20080249141A1 (en) * 2007-04-06 2008-10-09 Palepu Nageswara R Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
US8748648B2 (en) 2007-09-06 2014-06-10 Nektar Therapeutics Oligomer-calcium channel blocker conjugates
US8143314B1 (en) * 2007-09-13 2012-03-27 Robert Carl Stover Methods and formulations for treating ineffective or decreased esophageal motility
JP5292404B2 (ja) * 2007-09-21 2013-09-18 ハンオル バイオファーマ カンパニー，リミテッド Ｎ，ｎ−ジメチルイミドジカルボンイミド酸ジアミドのジカルボン酸塩、その製造方法、及びその薬剤学的組成物
EP2240163A1 (en) 2007-12-31 2010-10-20 Lupin Limited Pharmaceutical compositions of amlodipine and valsartan
EP2252578B1 (en) 2008-02-11 2012-08-01 Ramot at Tel Aviv University Ltd. Conjugates for treating neurodegenerative diseases and disorders
RU2359672C1 (ru) * 2008-02-18 2009-06-27 Зао "Биоком" Твердая лекарственная форма, предназначенная для лечения артериальной гипертензии и стенокардии, и способ ее получения
CN101564536B (zh) * 2008-04-21 2010-12-15 鲁南制药集团股份有限公司 一种治疗高血压的药物组合物缓控释制剂
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
KR20110025224A (ko) 2008-06-27 2011-03-09 아빌라 테라퓨틱스, 인크. 헤테로아릴 화합물 및 이의 용도
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US9290445B2 (en) * 2008-10-20 2016-03-22 Xenoport, Inc. Methods of synthesizing a levodopa ester prodrug
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
WO2010070705A1 (ja) * 2008-12-17 2010-06-24 株式会社メドレックス アムロジピンの安定な含水経口製剤
MY173823A (en) 2009-01-23 2020-02-24 Hanmi Science Co Ltd Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
EP2515876B1 (en) * 2009-11-09 2016-01-06 XenoPort, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
JP2013513600A (ja) 2009-12-09 2013-04-22 バイオラインアールエックス リミテッド 認知機能改善方法
PT2534153T (pt) 2010-02-12 2016-12-27 Pfizer Sais e polimorfos de 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona
JP2013520488A (ja) 2010-02-24 2013-06-06 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド ペルフェナジン−ｇａｂａのトリメシラート塩の結晶性形態物及びその製法方法
WO2011117876A1 (en) 2010-03-26 2011-09-29 Fdc Limited An improved process for the preparation of amlodipine free base and acid addition salts thereof
IT1400309B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
EP2425859A1 (en) 2010-08-08 2012-03-07 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Olmesartan formulations
AU2011289604C1 (en) * 2010-08-10 2016-04-21 Celgene Avilomics Research, Inc. Besylate salt of a BTK inhibitor
WO2012038963A1 (en) 2010-09-22 2012-03-29 Ramot At Tel-Aviv University Ltd. An acid addition salt of a nortriptyline-gaba conjugate and a process of preparing same
EP2635285B1 (en) 2010-11-01 2017-05-03 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
BR112013010564B1 (pt) 2010-11-01 2021-09-21 Celgene Car Llc Compostos heterocíclicos e composições compreendendo os mesmos
ES2665013T3 (es) 2010-11-10 2018-04-24 Celgene Car Llc Inhibidores de EGFR selectivos de mutante y usos de los mismos
WO2012071524A1 (en) * 2010-11-24 2012-05-31 Ratiopharm Gmbh Arylsulfonate salts of fingolimod and processes for preparation thereof
EP2770830A4 (en) 2011-10-28 2015-05-27 Celgene Avilomics Res Inc METHODS OF TREATING A DISEASE OR DISEASE ASSOCIATED WITH TYROSINE KINASE BTK (BRUTON'S TYROSINE KINASE)
JP6317319B2 (ja) 2012-03-15 2018-04-25 セルジーン シーエーアール エルエルシー 上皮成長因子受容体キナーゼ阻害剤の固体形態
JP6317320B2 (ja) 2012-03-15 2018-04-25 セルジーン シーエーアール エルエルシー 上皮成長因子受容体キナーゼ阻害剤の塩
EP2935226A4 (en) 2012-12-21 2016-11-02 Celgene Avilomics Res Inc HETEROARYL COMPOUNDS AND USES THEREOF
PL236001B1 (pl) 2012-12-21 2020-11-30 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję
SG11201505850WA (en) 2013-02-08 2015-08-28 Celgene Avilomics Res Inc Erk inhibitors and uses thereof
US20150374713A1 (en) 2013-02-08 2015-12-31 Wockhardt Limited Stable pharmeceutical composition of amlodipine and benazepril or salts thereof
SG11201507496UA (en) 2013-04-17 2015-11-27 Pfizer N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CN104529877A (zh) * 2015-01-22 2015-04-22 华东理工常熟研究院有限公司 氨氯地平-癸酸离子液体及其制备方法和用途
CN104610130A (zh) * 2015-01-22 2015-05-13 华东理工常熟研究院有限公司 氨氯地平-棕榈酸离子液体及其制备方法和用途
CN104523588A (zh) * 2015-01-22 2015-04-22 华东理工常熟研究院有限公司 氨氯地平-硬脂酸离子液体及其制备方法和用途
WO2017030893A1 (en) 2015-08-14 2017-02-23 Endocyte, Inc. Method of imaging with a chelating compound
WO2017068532A1 (en) 2015-10-23 2017-04-27 Ftf Pharma Private Limited Oral solution of dihydropyridine derivatives
CN105395495A (zh) * 2015-11-30 2016-03-16 宜昌东阳光长江药业股份有限公司 一种含有苯磺酸氨氯地平的组合物及其制备方法
EP3219309A1 (en) 2016-03-17 2017-09-20 K.H.S. Pharma Holding GmbH Fixed dosed pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension
US20200316029A1 (en) 2016-05-30 2020-10-08 Boehringer Ingelheim International Gmbh Fixed dose combination of telmisartan, hydrochlorothiazide and amlodipine
EP3522872B1 (en) 2016-10-07 2021-08-11 Silvergate Pharmaceuticals, Inc. Amlodipine formulations
US10350171B2 (en) 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same
EP3501502A1 (en) 2017-12-20 2019-06-26 Midas Pharma GmbH Fixed dosed pharmaceutical compositions comprising amlodipine, ramipril and atorvastatin
CN112334134A (zh) 2018-04-11 2021-02-05 希沃盖特制药公司 氨氯地平制剂
JP7470647B2 (ja) 2018-06-14 2024-04-18 アストラゼネカ・ユーケイ・リミテッド ジヒドロピリジン型カルシウムチャネル遮断薬医薬組成物を用いて血圧を低下させるための方法
PL3911648T3 (pl) 2019-01-18 2025-03-10 Astrazeneca Ab 6'-[[(1s,3s)-3-[[5-(difluorometoksy)-2- pirymidynylo]amino]cyklopentylo]amino][1(2h),3'-bipirydyn]-2-on jako inhibitor pcsk9 i sposoby jego zastosowania
US11253474B1 (en) 2021-02-01 2022-02-22 Liqmeds Worldwide Limited Pharmaceutical solution of amlodipine
EP4052695A1 (en) 2021-03-05 2022-09-07 Midas Pharma GmbH Stable oral fixed-dose immediate release pharmaceutical compositions comprising amlodipine, atorvastatin and candesartan cilexetil
WO2023285646A1 (en) 2021-07-15 2023-01-19 Adamed Pharma S.A A pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3816612A (en) * 1967-03-23 1974-06-11 Degussa Process for the production of basically reacting pharmaceuticals
US4032637A (en) * 1972-09-26 1977-06-28 Sandoz Ltd. Method of promoting sleep
US4177278A (en) * 1977-04-05 1979-12-04 Bayer Aktiengesellschaft 2-Alkyleneaminodihydropyridines compounds, their production and their medicinal use
JPS5547656A (en) * 1978-09-29 1980-04-04 Dainippon Pharmaceut Co Ltd 2-(2-substituted aminoethyl)-1,4-dihydropyridine derivative and its derivative
CS228917B2 (en) * 1981-03-14 1984-05-14 Pfizer Method of preparing substituted derivatives of 1,4-dihydropyridine
DK161312C (da) * 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
ZA839187B (en) * 1982-12-10 1984-07-25 Ciba Geigy Ag Amide compounds

Also Published As

Publication number Publication date
SE8701348D0 (sv) 1987-03-31
EG18266A (en) 1992-12-30
ATE49752T1 (de) 1990-02-15
FR2596758A1 (fr) 1987-10-09
CS236387A2 (en) 1989-01-12
YU58087A (en) 1988-08-31
EP0244944A3 (en) 1988-01-07
GB2188630A (en) 1987-10-07
NZ219868A (en) 1989-02-24
NO172181B (no) 1993-03-08
GB8608335D0 (en) 1986-05-08
CA1321393C (en) 1993-08-17
HUT43821A (en) 1987-12-28
FI871470A0 (fi) 1987-04-03
IL82101A (en) 1991-01-31
PT84611B (pt) 1989-11-30
IE59457B1 (en) 1994-02-23
SG59692G (en) 1992-12-04
KR870009998A (ko) 1987-11-30
AU7103087A (en) 1987-10-08
NL8700791A (nl) 1987-11-02
PL264982A1 (en) 1988-05-26
FI871470L (fi) 1987-10-05
SU1498388A3 (ru) 1989-07-30
AP50A (en) 1989-09-16
IN168414B (en:Method) 1991-03-30
ES2002599A6 (es) 1988-08-16
SE463457B (sv) 1990-11-26
DD265142A5 (de) 1989-02-22
MY101177A (en) 1991-07-31
ECSP941129A (es) 1994-12-15
CS353991A3 (en) 1992-04-15
CY1669A (en) 1993-05-14
DK170187A (da) 1987-10-05
UA6344A1 (uk) 1994-12-29
IL82101A0 (en) 1987-10-30
AU573123B2 (en) 1988-05-26
KR950006710B1 (ko) 1995-06-21
DK171708B1 (da) 1997-04-01
PT84611A (en) 1987-05-01
DE3710457A1 (de) 1987-10-08
IT1203853B (it) 1989-02-23
FR2596758B1 (fr) 1988-12-02
US4879303A (en) 1989-11-07
BG60698B2 (en) 1995-12-29
CZ289095B6 (cs) 2001-10-17
NO172181C (no) 1993-06-16
DE3761485D1 (de) 1990-03-01
CN87102493A (zh) 1987-10-14
PL149532B1 (en) 1990-02-28
LU86812A1 (fr) 1987-08-12
JPS62240660A (ja) 1987-10-21
SE8701348L (sv) 1987-10-05
GB2188630B (en) 1990-04-04
GR870525B (en) 1987-08-12
DK170187D0 (da) 1987-04-03
FI85017C (fi) 1992-02-25
CN1023800C (zh) 1994-02-16
NO871408L (no) 1987-10-05
PH24348A (en) 1990-06-13
HK76092A (en) 1992-10-09
EP0244944B1 (en) 1990-01-24
AR242562A1 (es) 1993-04-30
BE1000130A4 (fr) 1988-04-12
JPH037668B2 (en:Method) 1991-02-04
MA20938A1 (fr) 1987-12-31
MX5847A (es) 1993-08-01
ZA872439B (en) 1988-11-30
CS265237B2 (en) 1989-10-13
YU44801B (en) 1991-02-28
IE870869L (en) 1987-10-04
FI85017B (fi) 1991-11-15
SK278435B6 (en) 1997-05-07
HU196962B (en) 1989-02-28
IT8719977A0 (it) 1987-04-03
GB8707653D0 (en) 1987-05-07
GR3000394T3 (en) 1991-06-07
AP8700060A0 (en) 1987-02-01
NO871408D0 (no) 1987-04-03
EP0244944A2 (en) 1987-11-11

Similar Documents

Publication Publication Date Title
ES2012803B3 (es) Sales de amlodipina.
NO874939L (no) Substituerte basiske 2-aminotetraliner.
DE3767169D1 (de) Sportschuh.
DE3774909D1 (de) Antitumormittel.
DE3775679D1 (de) Vernebler.
ES2019949B3 (es) Propanaminas 3-ariloxi-3-sustituidas.
FI874044A0 (fi) Sackarosderivat.
DE3787141D1 (de) Nifedipinkombinationspräparat.
DE3779761D1 (de) Abseilgeraet.
DE3789216D1 (de) Schalter.
FI861224A0 (fi) Cirkulationsmassareaktor.
DE3771918D1 (de) Chinolinamide.
DE3785294D1 (de) Neigungsmesser.
DE3866077D1 (de) 4-aryl-5-carbamoyl-1,4-dihydropyridine.
DE3786679D1 (de) Schmitt-triggerschaltung.
DE3779158D1 (de) Chrom-dotierter scandium-borat-laser.
DE3773636D1 (de) Saeurebeschleunigte hydrocarboxilierung.
DE3771271D1 (de) Fluorphthalimide.
FI870567A0 (fi) Taetnings- och limaemne.
FI873437A0 (fi) Pyrimidinderivat.
DE3779382D1 (de) 3-6-diphenylpyridazine.
NO166102C (no) Ettergivende torsjonshylse.
NO874060L (no) Pulsformer.
DE3770459D1 (de) 3-halogensuccinimide.
ES2025152B3 (es) Soldador.